HER2 and HER3 are frequently overexpressed in cetuximab-resistant HNSCC, suggesting that dual or pan-HER inhibition may be required to achieve more durable responses [90]. This evidence concerns the gene ERBB2 and head and neck squamous cell carcinoma.